ALLR

Allarity Therapeutics Inc

NASDAQ

Add Alert

ALLR

Allarity Therapeutics Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Monksdream PremiumMember

04/18/24 2:44 PM

Post #307

Re: #305: @Acehole - "In addition, the company has entered into negotiations

You’re good at translating corporate speak
ALLR new 52 lo

Monksdream PremiumMember

04/17/24 2:15 PM

Post #306

Re: #303: @Acehole - Most pharmaceutical R&D companies are high risk poorly

ALLR new 52 lo

Acehole

04/17/24 1:09 PM

Post #305

"In addition, the company has entered into negotiations with key stakeholders, including warrant holders, to adjust the terms and conditions to make future capital raising more amenable, as well as negotiations to reduce other major liabilities. Finally, the Company has already started raising new equity by utilizing its existing ATM and expects to take further action so Allarity can meet the $2,500,000 equity requirement on the May 14, 2024 target date."

They plan on CONTINUING TO DUMP SHARES on the open market and DILUTING their shareholders with no end in sight.

"Our goal is to ensure that we can continue our development of stenoparib, strongly encouraged by the significant early data we have received so far from our ongoing monotherapy trial in advanced ovarian cancer."

In other words stenoparib is still not ready for phase 3. They are going to have to chemically modify it to try to improve it which means repeating phase 1 and phase 2 trials. They are going to need a A LOT more time and money and there is no guarantee at all that they can get it modified to the point it needs to be at.

This is a TOXIC investment. If there happens to be a pump, sell for what you can and get out. They are just going to continue with the reverse splits followed by dilution for the foreseeable future as they have no revenue, no product, and thomas jackass jensen needs to collect his handsome salary.

Bearish

BooDog

04/16/24 11:26 AM

Post #304

Re: #303: @Acehole - Most pharmaceutical R&D companies are high risk poorly

Good call imo. I was just surfing around Monks new 52 wk low calls. There's usually a good reason for that. Multiple RS's and offerings at the wrong time.

GL

Acehole

04/16/24 10:32 AM

Post #303

Most pharmaceutical R&D companies are high risk poorly run trash investments. Even by those standards ALLR is relative garbage. This is literally a bottom of the barrel company running purely off of lies and deceit by management. I’ve been investing for 15 years and have never see a company destroy their investors this aggressively and this quickly. Despite diluting us into oblivion, the market cap is again under $1 million as of today. Stenoparib clinical data is obviously showing that it is either not safe or not effective, otherwise this would not be happening. ALLR is DONE. Do NOT invest.

Acehole

04/12/24 7:04 PM

Post #302

Nothing to be bullish about here. This company is now a one trick pony. If stenoparib fails they are done. I'm thinking if stenoparib was doing as good as their last press release indicated then the price would be appreciating. Tread carefully as investing in this company is a gamble and I personally do not trust management.

Bearish

MetaMonster Free

04/12/24 2:02 PM

Post #300

Re: #298: @Money hunt - wrong answer as usual!!! Here come the Pharma bulls!!

New blood soaking up the float, is only a matter of time before we roar

Money hunt Free

04/12/24 2:00 PM

Post #299

Re: #290: @Monksdream - ALLR new 52 lo

Dirty short rats are going to get it up the ass power hour and TGIF

Money hunt Free

04/12/24 1:48 PM

Post #298

Re: #297: @Monksdream - Precious metals have the MOJO at present

wrong answer as usual!!! Here come the Pharma bulls!!

Monksdream PremiumMember

04/12/24 1:43 PM

Post #297

Re: #296: @Money hunt - The dip is in dude!! Let’s see if

Precious metals have the MOJO at present

Money hunt Free

04/12/24 1:41 PM

Post #296

Re: #292: @Monksdream - Early Barchart 100

The dip is in dude!! Let’s see if this baby has power!!!

Money hunt Free

04/12/24 1:38 PM

Post #295

Re: #291: @tw0122 - Hit it 200k float

FDA Green light will send this flying in outer space

Money hunt Free

04/12/24 1:37 PM

Post #294

Re: #293: @Monksdream - ALLR no 1 on the Barchart 100

No kidding!!! HiUge Short squeeze is imminent All holding for lift -off

Monksdream PremiumMember

04/12/24 9:48 AM

Post #293

ALLR no 1 on the Barchart 100

Monksdream PremiumMember

04/12/24 9:00 AM

Post #292

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

tw0122

04/12/24 6:16 AM

Post #291

Hit it 200k float

Monksdream PremiumMember

04/11/24 3:26 PM

Post #290

ALLR new 52 lo

2020trader Free

04/10/24 1:35 AM

Post #289

down 13% today , expecting lower

2020trader Free

04/09/24 12:11 AM

Post #288

DOWN 3% TODAY, EXPECTING LOWER

DK11

04/08/24 9:08 PM

Post #287

Trading Halt at 7:50 pm wonder if it has anything to do with the R/S

Triple nickle Free

04/04/24 12:32 PM

Post #286

Rs april 9 th 1/20

Monksdream PremiumMember

04/01/24 1:46 PM

Post #285

ALLR new 52 lo

stock1ace1 Free

03/28/24 6:22 PM

Post #284

Re: #283: @Triple nickle - Buy and hold,period

Why ?

Triple nickle Free

03/28/24 1:18 PM

Post #283

Buy and hold,period

Triple nickle Free

03/28/24 1:06 PM

Post #282

Picking up the dips

Monksdream PremiumMember

02/23/24 2:35 PM

Post #281

ALLR new 52 week low

Monksdream PremiumMember

02/15/24 4:35 AM

Post #280

Re: #273: @MiamiGent - ALLR Don't scrap with alley cat ALLR

ALLR new 52 week low

Invest-in-America Free

12/08/23 4:39 PM

Post #279

Re: #278: @WiseYoda - Thanks for the feedback

ALLR: Any time, Dude!!

PS: If I myself were running the USA, every 'Women' over 16 would be REQUIRED & AUTHORIZED to pack-a-firearm --- concealed, or otherwise --- and THEN see if America's MEN would still MESS with them!!! I.e., not merely regarding Wall Street STOCK issues regarding Women.

WiseYoda

12/08/23 4:30 PM

Post #278

Re: #277: @Invest-in-America - ALLR: As I have noted on several occasions

Thanks for the feedback

Invest-in-America Free

12/08/23 2:09 PM

Post #277

Re: #274: @WiseYoda - I don’t but Im tempted to jump in here…

ALLR: As I have noted on several occasions across the iHub platform, WOMENS issues simply do NOT gain much 'traction' on Wall Street, Dude. GOOD LUCK, if you nevertheless grab this one. (E.g., I did well on my @INST gamble today --- a Breast Cancer PR routine --- but had to DUMP it quickly into the Open Market in order to get the minimal profit I wanted.)

WiseYoda

12/08/23 12:56 PM

Post #276

52 week high $1852? Holy moly….

WiseYoda

12/08/23 12:43 PM

Post #275

Re: #274: @WiseYoda - I don’t but Im tempted to jump in here…

*know

WiseYoda

12/08/23 12:43 PM

Post #274

Re: #271: @Invest-in-America - ALLR: Maybe a 52-wk. HIGH , this time around???

I don’t but Im tempted to jump in here…

MiamiGent

12/05/23 10:40 AM

Post #273

ALLR Don't scrap with alley cat ALLR

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173360196

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173360286

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173360783

subslover

12/05/23 9:12 AM

Post #272

Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic

All evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor shrinkage including one complete response Early data follows Phase 2 dose optimization change from once-daily to twice-daily
Boston (December 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced encouraging initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of its PARP inhibitor, stenoparib, in women with advanced ovarian cancer (AOC). Of the five evaluable patients included in the initial data analysis, one patient experienced a complete response and the other four demonstrated stable disease.

Investigators prescreened women with AOC using Allarity’s DRP®-Stenoparib CDx, a complex transcriptomic signature comprising 414 mRNA biomarkers indicative of response/resistance to the drug. Each woman was assigned a DRP®-score, and those with scores above 50%, which suggested a higher likelihood of benefiting from treatment with stenoparib, were selected for treatment. Selected patients received stenoparib in a twice daily (BID) dosing regimen (200 mg morning, 400 mg evening) under a change in protocol, implemented earlier in the year, from prior once-daily dosing of 600 mg. Allarity implemented the protocol change to optimize the drug exposure taking into account the half-life of stenoparib in patients.

Of the 22 patients screened with the DRP®-Stenoparib CDx, 17 DRP® positive patients were identified. Eleven women have entered treatment, and among the five evaluable participants assessed up to the data evaluation cut-off, there were early signs of clinical benefit in all cases:

One patient experienced a complete response (CR) by scan (to be confirmed by second scan) and by decreased levels of CA125 (a biomarker of AOC).
One patient experienced stable disease with tumor shrinkage of 19%.
One patient experienced stable disease for more than 24 weeks with tumor shrinkage of 11%.
Two patients experienced stable disease with tumor shrinkage of 8%.
All five patients had previously been treated with another PARP inhibitor. All five patients remain in treatment with stenoparib and the four that did not have complete responses are showing stable disease at this time.

“We are enthusiastic about these early, promising data since the observed clinical benefit indicates that stenoparib is active in advanced ovarian cancer patients selected with the DRP® -Stenoparib CDx, even though these women had prior PARP inhibitor therapy and chemotherapy. While still early, these data suggest that BID dosing of this drug, and the use of the DRP® -Stenoparib CDx for patient selection and treatment, may provide advanced ovarian cancer patients meaningful benefit. The DRP® -Stenoparib CDx, if approved, may provide clinicians with an important diagnostic to guide patient treatment in this hard-to-treat patient population," said Marie Foegh, M.D., Chief Medical Officer of Allarity.

The initial data readout is from an ongoing Phase 2 open-label, single-arm trial that Allarity is conducting at multiple sites in the U.S. and Europe. The goal of the study is to evaluate the anti-tumor effect of stenoparib as monotherapy in DRP®-selected patients with locally recurrent or metastatic ovarian cancer after previous PARP inhibitor and chemotherapy treatments. The primary endpoint is objective response rate (ORR). Allarity anticipates an interim data readout in Q1 2024.

The DRP®-Stenoparib CDx is a transcriptomic signature comprising 414 mRNA biomarkers that are collectively predictive of tumor sensitivity or resistance to stenoparib. Using the DRP® CDx to select likely responder patients while excluding likely resistant ones, Allarity aims to improve the benefit-risk ratio of stenoparib in metastatic or locally advanced ovarian cancer. The initial data from Allarity’s ongoing DRP®-guided Phase 2 study of stenoparib suggests that the DRP®-Stenoparib CDx may identify a subset of AOC patients previously treated with a PARP inhibitor who may benefit from treatment with stenoparib. The DRP®-Stenoparib CDx is a clinical-stage companion diagnostic candidate and has not yet been approved by the U.S. FDA or the EU’s EMA.

All preliminary data are subject to change until the final study data readout. Early trial results may not be a reliable indicator of subsequent trial results based on a larger patient population.

About Stenoparib

Stenoparib is an orally-available, small molecule dual-targeted inhibitor of PARP1/2 and telomerase maintenance enzymes (Tankyrase 1 and 2). At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in the Wnt signaling pathway. Aberrant Wnt/ß-catenin signaling has been implicated in the development and progression of multiple cancers, potentially giving stenoparib a unique, dual tumor inhibitory action. Stenoparib was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has the exclusive, global rights for the development and commercialization of stenoparib.

Some approved PARP inhibitors have recently been shown to be associated with less favorable survival outcomes than initially established. Allarity’s Phase 2 trial data for stenoparib to date shows that the drug has much less myelotoxicity than the FDA approved PARP inhibitors. Specifically, in 42 evaluable women in Phase 2 studies with stenoparib, anemia (21%), neutropenia (2%) and thrombocytopenia (0%) was lower than the approved PARP inhibitor niraparib with anemia 51%, neutropenia in 20% and thrombocytopenia oberved in in 52% of 463 patients. Allarity anticipates that this lower myelotoxicity may make stenoparib a better candidate for combination with other drugs. Allarity is studying the therapeutic potential of stenoparib in combination with dovitinib (a pan-targeted kinase inhibitor) in an ongoing Phase 1b trial, with an anticipated data readout near early Q2 2024. The Company believes that stenoparib may have broad therapeutic potential in combination with other anti-tumor agents.

About Allarity Therapeutics
Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP® platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer, and in Phase 1 development for advanced solid tumors in a combination treatment with dovitinib, a pan-tyrosine kinase inhibitor (pan-TKI) that has previously been developed through Phase 3 in renal cancer; and IXEMPRA® (Ixabepilone), a microtubule inhibitor approved in the U.S. and marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, currently in Phase 2 development in Europe for the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS; and LiPlaCis®, a liposomal formulation of cisplatin and its accompanying DRP®, being developed via a partnership with CHOSA Oncolog